Global Oseltamivir Market Size study & Forecast, by Product (Capsule, Suspension, Other Product Types), by Application (Influenza A Influenza B, Other Applications), and Regional Analysis, 2023-2030

Global Oseltamivir Market Size study & Forecast, by Product (Capsule, Suspension, Other Product Types), by Application (Influenza A Influenza B, Other Applications), and Regional Analysis, 2023-2030

Global Oseltamivir Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Oseltamivir, commonly known by its brand name Tamiflu, is an antiviral medication used to treat and prevent influenza (flu) infections caused by the influenza A and B viruses. It belongs to a class of drugs known as neuraminidase inhibitors. Oseltamivir works by inhibiting the activity of the neuraminidase enzyme, which is essential for the influenza virus to spread and infect other cells in the body. Oseltamivir helps to reduce the severity and duration of flu symptoms and also decreases the risk of complications associated with the flu, such as pneumonia. The Oseltamivir market is expanding because of factors such as the rising prevalence of influenza virus infections and the increase in the number of research and development activities.

Infection with the influenza virus is becoming more common. Since influenza is known to be a substantial source of illness and mortality in people, treatments have been developed and put into place to lessen the financial and medical load. For instance, according to the Centers for Disease Control and Prevention data, the influenza virus infection caused 8–13 million symptomatic illnesses, 3.7–6.1 million medical visits, 82,000–170,000 hospitalizations, and 5,000–14,000 fatalities from early October 2021 to mid-June 2022. Over 2.8 million respiratory specimens underwent testing in clinical labs for the influenza virus. 98.6% of specimens for influenza A and 1.4% for influenza B both tested positive overall, making up 4.5% of the total. A positive result for influenza was found in 0.1% to 9.9% of the samples per week. Additionally, according to WHO statistics released in February 2021, approximately 490,516 specimens were analyzed in 2021–2022 by WHO GISRS laboratories. Of these, 12,368 tested positive for the flu, with 8,423 having influenza A and 3,945 having influenza B. As a result, the high prevalence of influenza infection in the population is anticipated to enhance the demand for the medicine oseltamivir for its treatment, driving the market's expansion. In addition, government initiatives to increase access to oseltamivir and rising healthcare expenditures are creating lucrative opportunities for market growth. However, the side effects associated with oseltamivir treatment and availability of alternative treatments stifle market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Oseltamivir Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the dominance of key market players, the rising prevalence of diseases, the presence of well-established healthcare infrastructure, and rising spending on research and development activities. Whereas, Asia Pacific is projected to have significant growth owing to factors such as rising disease prevalence, rising government funding for drug development, and rising healthcare expenditure in the region.

Major market player included in this report are:
F. Hoffmann-La Roche Ltd
Cipla Inc.
Zydus Cadila
NATCO Pharma Limited
Macleods Pharmaceuticals Ltd
Amneal Pharmaceuticals LLC
Alembic Pharmaceuticals Limited
Hetero Healthcare Limited
Lupin Limited
Strides Pharma Science Limited

Recent Developments in the Market:
In December 2022, The Administration for Strategic Preparedness and Response (ASPR) of the U.S. Department of Health and Human Services (HHS) has announced that it will make an additional supply of Tamiflu available to jurisdictions through the SNS.
In January 2022, Strides Pharma Science Ltd received approval from the American health organisation to market its generic version of oseltamivir phosphate for oral suspension, a medication used to treat influenza-related illnesses. These would lead to rise the company market share.

Global Oseltamivir Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Product, Application, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Product:
Capsule
Suspension
Other Product Types
By Application:
Influenza A
Influenza B
Other Applications

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
F. Hoffmann-La Roche Ltd
Cipla Inc.
Zydus Cadila
NATCO Pharma Limited
Macleods Pharmaceuticals Ltd
Amneal Pharmaceuticals LLC
Alembic Pharmaceuticals Limited
Hetero Healthcare Limited
Lupin Limited
Strides Pharma Science Limited

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.